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The term metabolism is derived from the Greek: μεταβολή metabolē meaning 
change and refers to the vast network of enzyme-catalyzed chemical conversions in 
an organism necessary for its maintenance, growth, reproduction and response to 
environmental changes. The earliest-documented metabolic experiment was 
performed by Santorio Santorio (1561-1636) known as the “weighing chair” 
experiment, which showed that the mass of ingested food is more than what is 
excreted, indicating the presence of dynamic metabolic processes in body. Metabolic 
processes can essentially be divided in catabolic processes, which generate energy 
by breaking down large molecules, and anabolic processes, which consume energy 
to synthesize large molecules. Carbohydrates (sugars), lipids (fats) and proteins 
make up the three main macronutrients providing the energy in our food. These three 
nutrients are absorbed by the gastrointestinal tract and broken down into smaller 
molecules via different pathways including glycolysis (monosaccharides), fatty acid 
oxidation (fatty acids) and trans/deamination (amino acids), for the production of 
ATP, the energy currency of life. 
Metabolic homeostasis, defined as the ability of an organism to maintain metabolic 
equilibrium, is determined by the delicate balance between anabolic and catabolic 
processes. Anabolic processes are directed to storage of energy and growth and are  
more dominant during feeding and the resting stage. Catabolic processes on the 
other hand are directed to energy utilization and breakdown and are associated with 
fasting or activity. In addition, environmental factors also substantially impact 
metabolism, such as the light-dark cycle (circadian rhythm), which regulates activity, 
sleep and the feeding and fasting response. An increase on either side of this 
balance introduces homeostatic disturbances and can ultimately lead to the 
development of metabolic diseases. 
In the following paragraphs, I will first give a brief overview of several aspects of 
energy metabolism relevant for this thesis, including glucose- and lipid metabolism, 
endocrine regulation of metabolism and the metabolic diseases type 2 diabetes and 
nonalcoholic fatty liver disease. After that I will provide an in-depth background on the 
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Glucose metabolism  
Glucose is the primary short-term energy fuel used by organisms because it is 
easier to metabolize than fatty acids and amino acids. It not only provides energy but 
also serves as an essential carbon source needed in almost all types of biosynthetic 
reactions. Glucose homeostasis is determined by the balance between glucose 
consumption (glycolysis and glycogenesis) and production (gluconeogenesis and 
glycogenolysis) and it is constantly controlled and tightly communicated across 
various tissues and organs. In its dysfunction, even small imbalances between 
energetic intake and expenditure can cumulatively result in drastic perturbations, 
which in turn influence organismal health. 
The majority of glucose derived 
from food is taken up by the skeletal 
muscle, liver and brain. After it has 
entered cells, glucose is converted into 
glucose-6-phosphate (G6P) via a 
phosphorylation reaction catalyzed by 
hexokinase in muscle and glucokinase 
(GK) in liver (Fig. 1). Subsequently, 
G6P is either oxidized to lactate and 
pyruvate to yield ATP via glycolysis, or 
is converted via glycogenesis into 
glycogen which represents the main 
storage form of glucose in the body. 
Glycogen, stored mainly in liver and 
muscle, can in turn be broken down 
into glucose via glycogenolysis to fulfill energy demands during fasting. Liver is the 
central organ in increasing plasma glucose concentrations by means of 
gluconeogenesis, a hepatic process that forms glucose primarily from lactate and 
amino acids during fasting and is catalyzed by the enzymes glucose-6-phosphatase 
(G6Pase) and phosphoenol-pyruvate carboxykinase (PEPCK). About 90% of non-
diet derived circulating glucose is produced by liver (Brandt, 1999). In contrast, 
muscle does not express G6Pase and therefore lacks the ability to produce glucose. 
 
Figure 1. Glucose metabolism, including glycolytic, 
gluconeogenic, glycogenic and glycogenolytic 
pathways. Adapted from Brandt (1999). 
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Lipid metabolism  
Due to their hydrophobic nature, lipids have a much higher energy density than 
carbohydrates and are therefore ideal for long-term energy storage. Since all lipids 
are hydrophobic and therefore insoluble in blood, they first need to be packed into 
hydrophilic lipoprotein particles for transportation. Triglycerides (TGs) account for 
about 95% of dietary lipids and after taken up by intestinal enterocytes are 
reassembled and packed together with cholesterol into chylomicrons, the largest 
lipoprotein particles (Fig. 2). Most TGs carried by chylomicrons are converted via a 
process called lipolysis into free fatty acids (FFAs) and glycerol by lipoprotein lipase 
(LPL) and then taken up by adipocytes and muscle cells for energy production or 
storage. In these tissues FFAs can be burnt in the mitochondria via a process called 
beta-oxidation, which generates acetyl-CoA that can be metabolized in the TCA cycle 
to yield ATP. Conversely, the synthesis of FFAs (lipogenesis) is accomplished in the 
cytoplasm by adding carbon units to acetyl-CoA. Adipose tissue and liver are main 
sites where lipogenesis takes place.  
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   The remaining chylomicrons, enriched in cholesterol, end up in liver which functions 
as the hub of lipid metabolism and in turn produces very-low-density lipoproteins 
(VLDL) used for exporting excess TGs into the circulation towards the peripheral 
tissues. Cholesterol-containing Low-density lipoproteins (LDL) metabolized from 
VLDL by hepatic lipase are mainly cleared by liver through hepatic LDL receptors 
(Lusis et al., 2004). However, when an excessive amount of LDL is present in the 
circulation, during feeding, macrophages will take up the circulating LDL via 
scavenger receptors. This action ultimately leads to the formation of foam cells and 
atherosclerotic plaques (Brown & Goldstein, 1983) (Fig. 2). In contrast to LDL, high-
density lipoproteins (HDL) are regarded as the “good” cholesterol and remove 
cholesterol from the peripheral tissues by taking it back to liver, a process known as 
reverse cholesterol transport (RCT) (Lewis & Rader, 2005).                              
 
Metabolic diseases 
In the last two decades, the number of people who suffer from metabolic diseases 
has dramatically increased. Especially obesity and diabetes are becoming pandemic 
diseases in both developed and developing countries, causing not only health issues 
but also enormous social and economic problems. Particularly, changes in dietary 
composition towards refined ingredients, high sugar and high fat have largely 
boosted the incidence of obesity, diabetes and cardiovascular disease. It now 
appears that our metabolic system that has evolved to efficiently extract energy from 
food is not able to cope with these recent changes in diet and life-style.  
In the following paragraphs, type 2 diabetes mellitus and non-alcoholic fatty liver 
disease, metabolic diseases which are most relevant to this thesis will be briefly 
discussed.   
 
Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2D) is a chronic metabolic disease affecting nearly 370 
million of the population worldwide in 2013 as reported by the International Diabetes 
Federation (IDF). It is one of the leading causes of mortality and is strongly 
associated with the western lifestyle featured by excessive food intake and lack of 
exercise. T2D is characterized by hyperglycemia (high blood sugar) caused by insulin 
resistance (IR) and resulting in a decreased utilization of glucose by adipose and 
muscle and an increased glucose production by liver. In the early stages of T2D 
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development, pancreatic β-cells can compensate for insulin resistance by increasing 
the production of insulin. However, eventually β-cell function declines and insulin 
production becomes inadequate to maintain glucose homeostasis. T2D is a complex 
disease that is caused by a complex interplay between genetic, epigenetic and 
environmental factors. While the major environmental factors, diet and activity level, 
are well known, identification of the genetic factors has been a challenge. Genome-
wide association studies (GWAS) have identified a dozen of genetic loci that are 
associated with increased risk of T2D. Among these loci, transcription factor 7-like 2  
gene (TCF7L2) and juxtaposed with another zinc finger protein 1 gene (JAZF1) have 
been shown as the two strongest risk factors associated with T2D development 
(Zeggini et al., 2008). Additional GWAS studies in different populations and 
combinatorial meta-analysis have further confirmed JAZF1 as a principal contributor 
in the development of T2D (Grarup et al., 2008; Langberg et al., 2012; Taneera et al., 
2012).  
Currently, metformin is the first-line oral medication in the treatment of T2D. If 
metformin and lifestyles changes aren't enough to control blood sugar levels, other 
oral or injected medications such as sulfonylureas (improve insulin secretion) or 
insulin can be added. Metformin lowers hyperglycemia by inhibiting hepatic glucose 
production via AMPK signaling. Metformin is generally well tolerated and safe but 
common side effects are diarrhea, nausea and lactic acidosis. Another class of 
effective anti-diabetic drugs are the thiazolidinediones (TZDs), which increase insulin 
sensitivity by activation of PPARγ. Despite their efficacy in glycemic control, TZDs 
are associated with various serious adverse side effects, including weight gain, fluid 
retention, osteoporosis and cardiovascular toxicity, which has strongly limited their 
clinical use and resulted in a collapse of the market for these drugs in 2007 (Lehrke & 
Lazar, 2005; Spiegelman & Tontonoz, 2008).Hence, the development of novel anti-
diabetic drugs which are more potent and specific for T2D is urgently required.          
 
Non-alcoholic fatty liver disease (NAFLD) 
NAFLD is the most common liver disease in the Western society. It is rapidly 
becoming a world-wide public health problem and is now the primary reason for liver 
transplantation. The hallmark of NAFLD is steatosis characterized by the excess lipid 
accumulation in hepatocytes, which is often self-limiting and regarded as a reversible 
process. Hepatic steatosis is a relatively benign and early condition of NAFLD, which 
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is strongly associated with obesity and insulin resistance. But, when accompanied by 
other metabolic disorders, it can progress to severe stages of NAFLD: 
steatohepatitis, cirrhosis and hepatocellular carcinoma (reviewed in Cohen et al., 
2011) (Fig. 3). The prevalence of NAFLD appears to be increasing, in part due to the 
increasing numbers of adult and pediatric individuals who are obese or overweight, or 
have metabolic syndrome or type 2 diabetes, all major risk factors for development of 
NAFLD. Current estimates are that ~20% of the general population has NAFLD.   
Recent research showed that accumulation of certain lipid species, such as 
diacylglycerol (DAG), long-chain acyl-CoA and ceramide, rather than triglyceride (TG) 
which is regarded as a benign lipid, are causing lipotoxicity by inducing serine 
phosphorylation of insulin substrate-1 (IRS-1) and thereby blocking hepatic insulin 
signalling (Samuel & Shulman, 2012). Causes of hepatic lipid accumulation include 
1) increased plasma levels of fatty acids due to increased intake of dietary fats and/or 
increased lipolysis in adipose tissue under obese and insulin resistant conditions; 2) 
enhanced de novo lipogenesis caused by increased levels of fatty acids and 
hyperinsulinemia; 3) decreased mitochondrial oxidation of fatty acids; and 4) 
diminished VLDL export (Kawano & Cohen, 2013). Depending on the size and 
number of fat droplets within the hepatocyte, steatosis is classified as macro- or 
micro-vesicular (Reddy & Rao, 2006).  
Based on the two-hit hypothesis (Day & James, 1998), steatosis is the first hit and 
can further progress into NASH after a second hit, such as oxidative-stress, ER-
stress, liver damage or accumulation of reactive oxygen species (ROS). NASH is an 
advanced stage in NAFLD and can be distinguished from simple steatosis by the 
presence of hepatic inflammation, hepatocyte ballooning and collagen deposition 
(fibrosis). Given that only a subset (10-20%) of steatosis patients develop NASH (Tilg 
& Moschen, 2010), it is still not clear whether steatosis is the main driver of NASH or 
whether NASH can develop independently via a distinct pathogenesis. The further 
Figure 3. The development of NAFLD, from steatosis, via NASH and fibrosis to cirrhosis. 
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progression of NASH leads to cirrhosis featured by severe cell death and the 
presence of scar tissue, which an eventually cause liver carcinoma and failure. 
Accumulating evidence indicates that cross-talk between liver and adipose tissue, 
established by various secreted cytokines and hormones, has obvious roles in 
determining NAFLD development. Especially the inflammatory cytokine TNFα has 
been shown in many studies to have a central role in promoting NASH development 
(Feldstein, 2010). In contrast, adiponectin which is exclusively secreted from adipose 
tissue has been shown to possess anti-lipogenic and anti-inflammatory effects in liver 
(Ouchi et al., 2000). Previous studies found a positive correlation between reduced 
serum levels of adiponectin and increased hepatic inflammation. Moreover, mRNA 
levels of both adiponectin and its receptors in liver were markedly decreased in 
NASH patients as compared to those with only steatosis, suggesting that 
hypoadiponectemia and an imbalance in the TNFα/adiponectin ratio could be drivers 
of NASH progression (Feldstein, 2010). As discussed, NAFLD is a complex disease 
affected by multiple factors at a systemic level rather than only a pure liver problem 
caused by local changes. Hence, an effective therapy for NAFLD should not only aim 
to directly treat the liver, but also be able to sensitize insulin activity and improve 
metabolic function in other tissues, particularly adipocytes and muscle.  
   Since there is no FDA-approved treatment for NAFLD/NASH, weight loss achieved 
through lifestyle modifications (diet and exercise) has been promoted as the standard 
treatment. This leaves considerable opportunity for the development of novel agents 
for the treatment of this disease. Current evidence shows that therapies showing the 
most promise in the treatment of NAFLD are the thiazolidinedione (TZD)-class of 
insulin sensitizers or PPARγ agonists acting to decrease hepatic lipid accumulation 
and attenuate the inflammatory response. Both pioglitazone and rosiglitazone, 
markedly (by 30–50%) reduce liver fat content in patients with type 2 diabetes (Bajaj 
et al., 2003; Juurinen et al., 2008). The decrease in liver fat with TZDs is of the same 
magnitude as can be achieved by 8% weight loss (-40%). Hepatic insulin sensitivity, 
when measured directly using the euglycemic insulin clamp technique combined with 
infusion of glucose tracers, has improved significantly with TZDs, and changes in 
liver fat and insulin action on hepatic glucose production have been closely 
correlated (Kotronen et al., 2008). 
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Endocrine regulation of metabolism 
To orchestrate the complex network of metabolic reactions between different 
tissues and organs and in response to external stimuli, a group of chemical 
messengers called hormones is produced and secreted from endocrine organs and 
glands, such as the hypothalamus, thyroid gland, thymus, pancreas and reproductive 
organs. Among the oldest documented endocrine studies date from 200 BC China 
describing the extraction of sex and pituitary hormones from human urine and 
medical use  (Temple, 2007). The pancreas is an essential endocrine organ that 
synthesizes and releases the two major hormones responsible for the endocrine 
regulation of glucose metabolism: insulin and glucagon. Following ingestion of a 
meal, insulin is produced by β-cells located in the islets of Langerhans of the 
pancreas and is secreted into the blood to promote glucose uptake and utilization 
(Fig. 4). Insulin primarily achieves its glucose lowering effect by stimulating glut4-
mediated glucose uptake in skeletal muscle and adipose tissue and by suppression 



















Figure 4. Summary of the endocrine functions of insulin (yellow) and glucagon (blue). 
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Nuclear Receptors in metabolic regulation 
Under normal conditions, metabolic homeostasis is achieved, in part, through the 
coordinated activities of members of the Nuclear Receptor (NR) family, a superfamily 
of ligand-modulated transcription factors (TFs) that mediate responses to a wide 
range of lipophilic signaling molecules including lipids, steroids, retinoids, hormones 
and xenobiotics (Sonoda et al., 2008). As sensors for these signals, they provide an 
important link between the environment and an organism’s physiological response. 
The NRs constitute one of the largest families of TFs in animals (48 genes in 
humans, 49 in mice) and include classic endocrine receptors that mediate the actions 
of steroid hormones, thyroid hormones, and the fat-soluble vitamins A and D, as well 
as a large number of so-called orphan nuclear receptors, whose ligands, target 
genes, and physiological functions are still largely unknown (Fig. 5).  
    Thanks to recent intensive research, legitimization of some of these orphans have 
revealed functions that are extremely interesting, particularly for the mechanistic 
characterization of metabolic diseases including T2DM. Currently, 13% of FDA-
approved therapeutics available on the market target the NR-family, including drugs 
for the treatment of insulin resistance (glitazones, TZDs), hyperlipidemia (fibrates), 
inflammation (dexamethasone) and cancer (tamoxifen) (Overington et al., 2006). 
Thus, NRs have become a primary target for drug development aimed at metabolic 
disease.  
 
The Nuclear Hormone Receptor Superfamily 
NRs are classified into three groups according to their ligand properties and 
physiological functions (Fig. 5). First, the endocrine receptors, which encompass 
receptors for the steroid hormones (GR, MR, AR, ER and PR), thyroid hormone 
(THR) and vitamin A and D (RARs, VDR), all of which have high ligand affinity and 
are essential for endocrine homeostasis. The second group is represented by the 
adopted orphan receptors, including PPARs, LXRs, FXR, PXR and CAR, which have 
a relatively low affinity for their ligands and functionally dimerize with RXRs. This 
second group also includes the enigmatic, or “obscure” orphan receptors (SF-1, LRH-
1, RORs and HNF-4) whose atypical ligands have been identified and shown to 
constitutively bind to receptors, yet the physiological meaning of their ligand-
dependent regulations has not been established. The third group consists of the 
orphan receptors whose ligand has not yet been identified.  
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At the structural level, NHRs are composed of an AF1 domain at the NH2-terminal 
region, a conserved DNA-binding domain (DBD) targeting specific DNA sequences 
called hormone response elements (HRE), a hinge region which exhibits flexibility in 
NHR dimerization, a unique ligand-binding domain (LBD) required for ligand 
interaction and receptor activation and a COOH-terminal region harboring the AF2 
domain needed for ligand-dependent transcriptional cofactor recruitment (Chawla et 









Figure 5. The nuclear receptor superfamily. Nuclear receptors can be subdivided into 
three or four groups, depending on the source and type of their ligand. Receptors with known 
physiological ligands are shown in color, and current orphan receptors are shown in gray 
(adapted from Chawla et al., 2001). 
 
Figure 6. Structure and binding of Nuclear Receptors. (A) Schematic structure of a typical 
nuclear receptor is shown (see text for details); (B) Schematic diagrams for NHR dimerization 
and DNA binding motifs. From left to right, homodimer of endocrine receptor, RXR heterodimer 
and monomeric orphan receptor. Arrows represent the AGGTCA consensus recognition 
sequence of a variant (adapted from Chawla et al., 2001). 
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    A HRE typically contains two consensus AGGTC hexa-nucleotide motifs or 
variants thereof with a spacing of n (where n = 0-5) nucleotides (Sandelin & 
Wasserman, 2005). Based on the orientation of the hexamers, HREs are categorized 
as palindrome (inverted repeat), direct repeat or half-site (in the case of monomeric 
binding) (Fig. 6B).  
 
RXRs, the common companion of NR heterodimers 
The identification of 9-cis retinoic acid, a vitamin A derivative, as the endogenous 
ligand of retinoid x receptor (RXR) was the first “deorphanization” of an orphan 
nuclear receptor and marked start of the era of “reverse endocrinology” in which a 
receptor is used as the cue to identify its ligand (Evans & Mangelsdorf, 2014). RXRs 
serve as obligate partners for many NHRs to form functional heterodimers and 
control crucial metabolic pathways, including lipid metabolism, since all lipid-sensing 
receptors (PPARs, LXRs, FXR) are RXR heterodimers (Fig. 6B). The underlying 
feature resulting from receptor hetero-dimerization is that either RXR ligand or the 
partner ligand can mediate consequential physiological outcomes. In comparison with 
a homodimeric or monomeric receptor, this dual-ligand regulation thus enables two 
partner receptors to have cooperative and complementary effects. Furthermore, this 
dual-ligand mechanism also allows synergistic responses by which trace amounts of 
ligands, especially for the low-affinity lipid sensing receptors, or small changes in 
ligand concentration can result in a profound biological response. 
 
The PPAR subfamily of lipid sensors  
The peroxisome proliferator-activated receptor (PPAR) subfamily of NRs consists 
of three members: α, β/δ and γ, all of which are activated by various dietary lipids, 
particularly by polyunsaturated fatty acids (PUFAs). The PPARs are the most 
intensively studied members of the nuclear receptor family in the last decade. Their 
unique lipid-sensing properties and metabolic functions in metabolism makes the 
PPARs potent therapeutic targets for drug development.  
PPARα is the molecular target of the fibrate class of lipid-lowering drugs and is 
primarily expressed in tissues with a high level of fatty acid catabolism such as liver, 
brown fat, kidney, heart and skeletal muscle where it regulates fatty acid oxidation 
and apolipoprotein synthesis during fasting (Contreras et al., 2013). PPARα is also 
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present in the vascular wall and in human macrophages (foam cells) where it is 
considered to have anti-inflammatory and anti-atherogenic effects.  
PPARγ has been identified as the master regulator of adipogenesis and is 
abundantly expressed in adipose tissue. In contrast to PPARα, PPARγ facilitates 
energy conservation by promoting fat storage through increasing the differentiation of 
adipocytes and expression of important lipogenic proteins. Importantly, PPARγ plays 
an important role in insulin sensitization and has been identified as the molecular 
target of the thiazolidinedione (TZD) class of insulin-sensitizing drugs (Tontonoz & 
Spiegelman, 2008). The molecular mechanisms by which TZDs mediate their insulin 
sensitizing effects are still poorly understood, but it is clear that adipose tissue plays 
a central role in their action (He et al., 2003; Hevener et al., 2003). Although PPARγ 
is predominantly expressed in adipose tissue, muscle and liver are the major tissues 
of insulin-responsive glucose homeostasis (Tontonoz & Spiegelman, 2008). Adipose-
specific PPARg knockout mice, when challenged with a high-fat diet (HFD), develop 
systemic insulin resistance and it is believed that these systemic effects are mediated 
through the release of adipokines such as adiponectin, leptin and resistin (He et al., 
2003). Like PPARα, PPARγ has been shown to have anti-atherogenic actions in 
macrophages, resulting from its anti-inflammatory effect as well as through activation 
of reverse cholesterol transport (Chinetti et al., 2001). Paradoxically, PPARγ 
enhances insulin sensitivity while it also induces adipogenesis and lipid storage in 
adipose which are known to promote insulin resistance. Thus, the development of 
selective PPARγ ligands with potent insulin sensitizing properties but without 
adipogenic and lipogenic effects would be a promising alternative to overcome the 
known side effects of TZDs, such as body weight gain caused by full PPARγ 
activation.  
PPARδ (also known as PPARβ) is ubiquitously expressed and when activated it 
promotes fatty acid oxidation, thermogenesis and overall energy expenditure (Reilly 
and Lee, 2008). PPARδ deficient mice are prone to obesity and insulin resistance 
when challenged with a high-fat diet. Conversely, transgenic expression of a 
constitutively active form of PPARδ in adipose tissue or skeletal muscle protects mice 
from diet-induced obesity and regulates muscle fiber type switching, respectively 
(Wang et al., 2003; 2004). 
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Orphan nuclear receptor TR4 
TR4 (TAK1, NR2C2), together with the closely related transcription factor TR2 
(NR2C1), form a subclass of the NHR superfamily. TR4 is considered to be an 
orphan receptor (e.g. a receptor of which the natural ligand has not yet been 
identified) but recent reports suggest that certain fatty acids and eicosanoids 
enhance its transcriptional activity, thereby indicating that TR4 might function as a 
lipid sensor similar to the PPAR subfamily of NHRs (Tsai et al., 2009; Xie et al., 
2009). TR4 has the highest expression of all NHRs in pancreatic islets and β-cells 
but is also expressed in other metabolically important tissues, including liver, adipose 
tissue and muscle (Bookout et al., 2006; Chuang et al., 2008) (Fig. 7). The 
physiological relevance of TR4 however, is still largely unknown. Whole body TR4 
knockout mice have been described previously but these mice display a complex 
phenotype including developmental and behavioral abnormalities as well as growth 
retardation, low IGF serum levels and perinatal and early postnatal hypoglycemia, 
which complicates the analysis of metabolic abnormalities (Collins et al., 2004). It 
thus remains to be determined to what extent these effects and phenotypes are a 
directly or indirectly mediated by TR4.  
 
A             B 
 
Figure 7 Comparative Expression Levels of the 49 NHRs for Mouse Islets and MIN6 β-
cells. TR4 is the most abundant NHR in (A) mouse islets and (B) MIN6 β-cells (Bookout et 
al., 2006). 
 
TR4 structure and ligand activation 
Like other NRs, TR4 has a variable N-terminal domain, a conserved DNA binding 
domain (DBD) and a ligand binding domain (LBD) which modulates gene 
transcription upon ligand binding. TR4 can bind as a homodimer or heterodimer with 
its highly homologous receptor TR2 to hormone-response-elements (HREs) 
containing direct repeats with the consensus sequence AGGTCA and a spacing of 1 
to 5 nucleotides (DR1-5). The preferred response element of TR4, however, is a DR1 
which is also activated by the PPARs (Lee et al., 2002). 
  Introduction 




Although the specific ligand for TR4 has not been found yet, recent studies 
showed that certain PUFAs and their metabolites, such as γ-linoleic acid and 13-
hydroxyoctadecadienoic acid (13-HODE) facilitate the transcriptional activity of TR4, 
suggesting that TR4 might serve as a potential lipid sensor similar to PPARs (Tsai et 
al., 2009; Xie et al., 2009). In addition, the thiazolidinedione (TZD) class of anti-
diabetic drugs have also been shown to transactivate TR4 to a similar degree as 
PPARγ (Xie et al., 2009). This overlap in ligand and target specificity between TR4 
and PPARγ raises questions about how the functional redundancy of these 
receptors. 
 
Posttranslational regulation of TR4 
Upstream effectors, like the energy sensor AMP-activated protein kinase (AMPK) 
and mitogen-activated protein kinase (MAPK) signaling pathways also affect TR4 
activity, pointing towards a role for TR4 in energy sensing (Huq et al., 2006; Kim et 
al., 2011). Kim et al. (2011) showed that inhibition of AMPK by the compound C 
inhibitor resulted in the activation of TR4 transcriptional activity, whereas activation of 
AMPK by metformin or AICAR suppressed TR4 activity. In another study, Huq et al. 
(2006) showed that TR4 could also be phosphorylated by MAPK at its AF-1 domain 
and that activation of MAPK by anisomycin could suppress TR4 transactivation. 
Conversely, inhibition of MAPK by PD98059 enhanced the TR4 transactivation.  
Mechanistically, is was demonstrated that MAPK-mediated TR4 phosphorylation 
renders TR4 as a repressor via recruiting co-repressor RIP140. In contrast, hypo-
phosphorylation rendered TR4 an activator via recruitment of co-activator PCAF (Huq 
et al., 2006). In addition, cofactors TRA16 and JAZF1 (TIP27), have also been shown 
to modulate TR4 transcription activity via direct binding to TR4 (Lin et al., 2014). 
TRA16 was identified as a selective TR4 co-repressor since it prevents TR4 from 
binding to DNA and/or blocks the interaction between DBD and LBD of TR4 (Yang et 
al., 2003). Co-repressor JAZF1 will be discussed in more detail below. 
 
Evidence for TR4 as a master regulator of energy homeostasis 
A link with energy homeostasis has been made previously by the group of 
Chawnshang Chang who demonstrated that TR4 regulates the expression of 
phosphoenolpyruvate carboxylase (PEPCK) and stearoyl-CoA desaturase 1 (SCD1), 
key enzymes in hepatic gluconeogenesis and lipogenesis, respectively (Liu et al., 
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2007; Kim et al., 2011). Whole body TR4 knockout mice showed decreased hepatic 
PEPCK gene expression and hepatic glucose production, resulting in fasting 
hypoglycemia. In contrast, overexpression of TR4 induced PEPCK gene expression 
and hepatic glucose production in both human and mouse hepatocytes (Liu et al., 
2007). Kim et al. (2011) demonstrated that TR4 transcriptionally modulates the 
expression of SCD1 through direct binding to its promoter. SCD1 is the rate limiting 
enzyme in the biosynthesis of mono-unsaturated fatty acid, and has key roles in 
obesity, diabetes, lipogenesis, β-oxidation and insulin sensitivity (Cohen & Friedman, 
2004). TR4 knockout mice exhibited decreased expression of SCD1 in liver, reduced 
fat mass and increased insulin sensitivity with increased β-oxidation and decreased 
lipogenic gene expression (Kim et al., 2011). In adipocytes, TR4 has been shown to 
increase the expression of the fatty acid transport protein 1 (FATP1) gene, which 
encodes a membrane receptor crucial for fatty acid uptake into adipocytes (Choi et 
al., 2011). In addition, cluster of differentiation 36 (CD36), another receptor involved 
in lipid uptake, and the ApoE gene, which has a key role in cholesterol transport were 











Figure 8. Metabolic functions of TR4. Top, regulation of TR4 activity by MAPK and AMPK-
mediated (de)phosphorylation, cAMP/PKA signaling, PUFAs and transcriptional co-factors; 
Bottom, known target genes and metabolic functions of TR4; Left and right, unknown TR4 
metabolic functions in pancreas and muscle.    
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Finally, TR4 was identified as a critical regulator of glucose homeostasis through 
its regulation of pituitary adrenocorticotrophic hormone (ACTH) secretion and the 
production of glucocorticoids (Fig. 8). Importantly, those findings provided a direct link 
between TR4 and the etiology of Cushing disease (Du et al., 2013).  
 
JAZF1, a repressor of TR4, is associated with insulin release and T2D 
Genome-wide association studies (GWAS) have recently identified several new 
genetic variants associated with the development of type 2 diabetes. One of these 
risk loci, specifically related to defects in insulin release, encodes the protein JAZF1 
(alternative name TIP27), a 27 kDa nuclear protein containing three putative zinc 
finger motifs with unknown function (Zeggini et al., 2008; Lyssenko et al., 2008; 
Grarup et al., 2008). Overexpression of JAZF1 in mice led to reduced total 
cholesterol and fasting plasma insulin levels, and enhanced glucose tolerance and 
insulin sensitivity. Hyperinsulinemic-euglycemic clamp experiments further 
demonstrated that HFD-fed JAZF1-Tg mice had lower hepatic glucose production 
and higher insulin sensitivity compared with nontransgenic littermates. In addition, the 
hepatic expressions of PEPCK, Glucose-6-phosphatase (G6Pase) mRNAs and 
proteins, were significantly decreased, whereas the phosphorylation of insulin-
receptor (InsR), IRS-1, adenosine monophosphate activated protein kinase (AMPK) 
and Akt kinase (Akt) in the liver was significantly increased in HFD-fed TIP27-Tg 
mice compared with nontransgenic littermates (Yuan et al., 2015). Together, these 
findings point towards a TR4/JAZF1 complex important for maintenance of glucose 
homeostasis and the development of T2D. 
    In conclusion, TR4 has prominent roles in maintaining metabolic homeostasis 
through regulating a number of genes essential for both glucose and lipid 
metabolism. As a ligand-dependent nuclear receptor, TR4 might thus provide a novel 
therapeutic target in the management of glucose homeostasis and prevention or 
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Fibroblast growth factor signaling in metabolic regulation  
 
This section is adapted from:  
Nies VJ, Sancar G, Liu W, van Zutphen T, Struik D, Yu RT, Atkins AR, Evans RM, 
Jonker JW, Downes MR (2016) Fibroblast Growth Factor Signaling in Metabolic 
Regulation.Front Endocrinol (Lausanne). 2016 Jan 19;6:193. 
 
The emergence of Fibroblast Growth Factors as metabolic hormones  
Fibroblast growth factors (FGFs) are secreted signaling proteins with wide ranging 
functions in cell proliferation, development and wound healing (Mohammadi et al., 
2005; Beenken & Mohammadi, 2009). FGFs act as autocrine, paracrine and/or 
endocrine hormones by binding to FGF receptors (FGFRs). FGFR dimerization 
induces the activation of downstream signaling cascades. Over the past two 
decades, several FGFs have been linked to metabolism by the discovery that they 
are transcriptionally regulated by members of the nuclear receptor (NR) superfamily 
of ligand-activated transcription factors (Jonker et al., 2012; Kharitonenkov et al., 
2005; Tomlinson et al., 2002; Shimada et al., 2004). These FGFs have been 
demonstrated to mediate some of the effects of these NRs in the regulation of 
glucose and lipid metabolism (Jonker et al., 2012), (Inagaki et al., 2005; Inagaki et 
al., 2007). Currently three members have been linked to regulation of energy 
metabolism: FGF1, FGF15/19 (with FGF15 being the mouse orthologue of human 
FGF19), and FGF21 (Jonker et al., 2012; Kharitonenkov et al., 2005; Tomlinson et 
al., 2002; Shimada et al., 2004). FGF1 is critical for adipose function and is regulated 
by the lipid sensor PPARγ, FGF15/19 modulates bile acid metabolism and is 
regulated by the bile acid sensor farnesoid X receptor (FXR), and FGF21 regulates 
the adaptive fasting response and is a target of the fatty acid sensor PPARα (Jonker 
et al., 2012; Inagaki et al., 2005; Inagaki et al., 2007).   
FGF15/19 is considered a regulator of the feeding response. In response to food 
intake, a postprandial flux of bile acids is released into the small intestine followed by 
activation of FXR expressed in the terminal ileum, which results in increased 
transcription of FGF15/19 (Inagaki et al., 2005). FGF15/19 enters the circulation and 
binds to the FGFR4/β-klotho receptor complex on the cell membrane of hepatocytes, 
ultimately leading to repression of gluconeogenesis and stimulation of glycogen and 
protein synthesis (Kir et al., 2011).  
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 FGF21 is considered a typical fasting hormone and although seemingly 
paradoxical, circulating FGF21 levels are also elevated during obesity (Hale et al., 
2012). The link between obesity and prolonged fasting is that they are both 
characterized by increased levels of circulating free fatty acids, which can activate 
PPARα in the liver, leading to upregulation of FGF21 (Mai et al., 2009). In addition, 
FGF21 is secreted by the muscle during situations of metabolic stress (reviewed in 
Luo & McKeehan, 2013). FGF21 acts on different tissues, including brain, adipose 
tissues, pancreas and the liver (reviewed in Owen et al., 2014).  
FGF1 is expressed in several tissues including the liver, kidney and brain, but 
most notably it is highly upregulated in white adipose tissue (WAT) following a high 
fat diet (HFD) challenge. Experiments with FGF1 KO mice revealed that this growth 
factor is indispensable for WAT remodeling in response to feeding and fasting. Mice 
lacking FGF1 are unable to properly expand their WAT during increased nutrient 
load, and upon withdrawal of the HFD, also have problems in WAT reduction (Jonker 
et al., 2012)(Fig. 9).  
 
Figure 9. Summarization of the major metabolic effects of pharmacological 
administration of FGF1, FGF19 and FGF21. FGF1 and FGF19 can affect metabolism when 
infused directly into the brain. However, it is currently unclear to what extent they cross the 
BBB when peripherally administered, and whether the concentration that reaches the brain 
influences whole body physiology.  For FGF21, it has been shown that its central actions 
contribute considerably to its pharmacological effects. All three FGFs are thought to affect 
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whole body metabolism via signaling in the WAT. In addition, FGF19 also acts via the liver. 
(Nies et al., 2016) 
 
When overexpressed or pharmacologically administered to obese, diabetic 
animals, FGF1, FGF19 and FGF21 all greatly improve the metabolic profile (Suh et 
al., 2014; Kharitonenkov et al., 2005; Fu et al., 2004). Acute effects include lowering 
of blood glucose and insulin levels (Suh et al., 2014; Adams et al., 2013). Chronic 
administration of any one of these FGFs results in increased insulin sensitivity, 
reduced hepatic steatosis, and improved serum lipid profiles. FGF15/19 and FGF21 
also promote weight loss (Adams et al., 2013). FGF1, FGF19 and FGF21 regulate 
different metabolic processes through different cell types and tissues, of which the 
WAT, CNS and the liver seem to be the main players (Jonker et al., 2012; Suh et al., 
2014; Kharitonenkov et al., 2005; Kir et al., 2011; Adams et al., 2013; Luo & 
McKeehan., 2013b; Owen et al., 2014)(Fig. 9). In addition BAT, pancreas, muscle 
and are involved in FGF signaling by being a source of FGFs, a target, or both 
(Straub & Wolfrum, 2015; Wente et al., 2006; Mashili et al., 2011; Hsuchou et al., 
2007; Morton et al., 2013; Hanai et al., 1989). 
FGF1, FGF15/19, FGF21 and their targets provide interesting therapeutic 
possibilities for the treatment of metabolic diseases, such as obesity, non-alcoholic 
fatty liver disease, type 2 diabetes and atherosclerosis (Kharitonenkov et al., 2005; 
Jonker et al., 2012; Fu et al., 2004). Despite their spectacular metabolic properties, 
the native FGFs do not have the optimal characteristics to be used as a drug in the 
clinic (Wu et al., 2010; Kharitonenkov et al., 2013). However, considerable progress 
has been made in the development of highly improved FGF mutants and variants, of 
which one already entered a clinical trial (Gaich et al., 2013). 
 
The FGF signaling machinery  
The FGF family consists of 18 members affecting a variety of processes through 
induction of intracellular signaling via their cognate receptors, the FGFRs (Fon Tacer 
et al., 2010). There are four FGFRs (FGFR1-4) with an intracellular tyrosine kinase 
domain, and one that lacks this domain (FGFRL1/FGFR5) (Sleeman et al., 2001). 
Depending on the tissue, alternative splicing of these genes gives rise to a total of 7 
different isoforms (FGFR1b, FGFR1c, FGFR2b, FGFR2c, FGFR3b, FGFR3c, and 
FGFR4) due to the alternative use of exon IIIb or IIIc (Fon Tacer et al., 2010).  
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FGF1 is often called the universal ligand as it can bind and activate all FGFRs 
(Eswarakumar et al., 2005). It does however require polysulfated polysaccharides 
such as HPSGs or heparin on the cell membrane to form a stable signaling complex 
to induce efficient signaling (Harmer et al., 2004). These polysaccharides are present 
on the cell membrane of almost all cell types. It is thought that the high affinity of 
FGF1 and other canonical FGFs for the HPSGs restricts their activity to the vicinity of 
its secretory point, and that they therefore mainly act as autocrine or paracrine 
factors (Itoh, 2010). The interaction of FGF1 with integrins, another type of cell 
surface receptor, also contributes to its activity (Mori et al., 2008; Rusnati et al., 
1997). 
FGF15/19 and FGF21 have lower affinities for HSPGs and thus can circulate 
through the body. They rely on the membrane–bound co-receptor β-klotho to 
establish FGFR activation (Goetz et al., 2007; Ogawa et al., 2007). Depending on the 
secreting tissue, FGF15/19 and FGF21 can act as endocrine and/or autocrine 
factors. FGF21 mainly binds to FGFR1, while FGF19 associates with both FGFR1 
and FGFR4 to a similar extent (Yang et al., 2012). The tissue specific activity of an 
FGF is thus determined by its affinity for the different FGFRs together with its 
requirement for binding to polysulfated polysaccharides, β-klotho and integrins 
(Zhang et al., 2006). 
Binding of an FGF to its receptors and cofactors induces dimerization and 
subsequent phosphorylation of the receptor intracellular tyrosine kinase domains, 
which then function as docking sites for other signaling proteins (Dailey et al., 2005). 
Two main signaling proteins that associate with FGFRs upon receptor activation are 
phospholipase C (PLCγ) (Peters et al., 1992) and FGF receptor substrate 2 (FRS2) 
(Kouhara et al., 1997). PLCγ links FGFR activation to downstream changes in 
diacylglycerol (DAG), inositol triphosphate (IP3), intracellular Ca2+ levels and 
activation of protein kinase Cs (PKCs). FRS2 facilitates the assembly of a scaffold 
complex (consisting of protein tyrosine phosphatase, non-receptor type 11 (Shp2), 
growth factor receptor-bound protein 2 (Grb2) and GRB2-associated-binding protein 
1 (GAB1) that mediates Ras/MAPK/ERK and PI3K-Akt signaling (Dailey et al., 2005; 
Eswarakumar et al., 2005; Gotoh, 2008). Other studies showed that FGFRs can 
stimulate STAT3 activation(Hart et al., 2000). FGF-induced downstream signaling 
pathways and concomitant intracellular changes are tissue- and cell-dependent.  
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The expression of β-klotho, FGFR1c and FGFR2c are downregulated in WAT 
during obesity and inflammation (Díaz-Delfín et al., 2012). Pancreatic β-klotho is 
downregulated under hyperglycemic conditions (So et al., 2013). This indicates that 
FGF signaling is not only regulated by the time- and tissue-dependent expression of 
the ligands, but also by their signaling machinery, which can be affected by 
pathological conditions. This further substantiates the intricate interplay between 
FGFs, receptors and cofactors, and their effect on metabolic homeostasis.   
 
FGF signaling in white adipose tissue (WAT)  
    Adipocytes express both β-klotho and FGFRs (mainly FGFR1c and FGFR2c) and 
are therefore putative targets for FGFs (Suzuki et al., 2008). WAT is also a source of 
FGFs, of which FGF1 and FGF21 are most relevant in the adult (Jonker et al., 2012; 
Dutchak et al., 2012). The adipose-tissue specific FGFR1 KO mouse model has been 
particularly useful in unravelling the contribution of the WAT to the beneficial effects 
of FGFs on metabolism. However, these mice were generated by Cre-recombinase 
mediated deletion using the aP2 promoter, which is known for its ectopic expression 
in macrophages and neuronal cells (Martens et al., 2010). Several brain areas also 
express FGFR1, and have been shown to be involved in regulating responses to 
FGFs (Bookout et al., 2013; Sarruf et al., 2010). It is unknown whether there are 
neurons that co-express aP2 and FGFR1, which would result in excision of FGFR1, 
and defective FGFR1 signaling in the brain. Therefore, conclusions based on this 
model should be drawn with some caution.  
    Compared to lean controls, obese patients display a higher subcutaneous WAT-
specific secretion of FGF1, as determined by ex vivo secretion assays (Mejhert et al., 
2010). Adipose-derived FGF1 does not enter the circulation, suggesting that it acts 
locally (Mejhert et al., 2010). In mice, high fat diet feeding induces PPARγ-regulated 
FGF1 expression in visceral WAT, where it regulates responses to nutrient 
fluctuations. Knockout of FGF1 results in a defective response to HFD feeding, 
characterized by aberrant WAT expansion and impaired WAT vascularization, the 
rapid development of severe diabetes, and defective WAT reduction upon HFD 
withdrawal (Jonker et al., 2012). In contrast, FGF1 KO mice maintained on a normal 
chow diet show no obvious phenotype and appear completely normal.  
    How FGF1 is involved in the expansion of adipose tissue during HFD feeding is 
not completely understood. However, there is evidence that FGF1 promotes pre-
  Introduction 




adipocyte proliferation and differentiation, and that ERK1/2 signaling is central to 
these processes (Hutley et al., 2004; Newell et al., 2006). In addition, since FGF1 
promotes angiogenesis, it is likely that locally produced FGF1 contributes to the 
expansion of WAT by stimulating vascularization (Murakami & Simons, 2008). This 
hypothesis is supported by the finding that FGF1 KO mice show reduced 
vascularization of WAT after HFD feeding compared to control animals (Jonker et al., 
2012).  
    Because FGF1 is downstream of PPARγ, a well-known target for the 
thiazolidinedione (TZD) class of anti-diabetic drugs, it was hypothesized that FGF1 
mediates a subset of PPARγ-activated genes, and by doing so improves the 
metabolic profile. Indeed it has been shown that pharmacological administration of 
FGF1 normalized blood glucose levels within an hour in obese, diabetic rodents. 
Chronic administration resulted in normoglycemia, insulin sensitization and reduced 
hepatosteatosis (fatty liver). The acute blood glucose lowering effect seems to be 
dependent on FGFR1 signaling in WAT, since WAT-specific deletion of this factor 
abrogated FGF1-induced normoglycemia in obese, hyperglycemic mice. Whether the 
other metabolic improvements (i.e. reduction of hepatic steatosis) are dependent on 
WAT signaling is unknown. 
 
FGF mutants and FGFR antibodies: promising perspectives for FGF based 
pharmacologic treatments 
The finding that FGFs play important roles in metabolic regulation offers new 
therapeutic options for the treatment of metabolic disorders. However, despite their 
spectacular effects in rodents, wild-type FGFs have several drawbacks for use in 
patients. They have various adverse effects, are expensive and labor-intensive to 
produce, not suitable for large-scale production, and/or have poor stability and short 
half-life, which currently holds back their application (Wei et al., 2012; Wu et al., 
2010; Xia et al., 2012; Kharitonenkov et al., 2013; Suh et al., 2014). To circumvent 
this, several attempts have been made to improve the FGFs so that they are more 
stable, retain or improve their beneficial effects on metabolism, and lose their side-
effects.  
The main concern that limits the application of FGF1 and FGF19 is that they have 
been linked to cellular proliferation and tumor formation (Schumacher et al., 1998; 
Gospodarowicz, 1975; Nicholes et al., 2002). Although there are no indications that 
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FGF21 is mitogenic, its chronic administration has been associated with bone loss 
(Wei et al., 2012). In addition FGF1 and FGF21 have low in vivo stability, which 
would make treatment expensive and require multiple injections per week (Xia et al., 
2012; Kharitonenkov et al., 2013). With regard to FGF1 and FGF19, attempts have 
been made to identify sequences within the peptide responsible for mediating the 
proliferative responses, and whether they can be deleted while retaining the 
metabolic properties. From studies with FGFR1 and FGFR4 KO mice and studies 
with FGF19 mutants that show differential binding preference towards FGFR1 and 
FGFR4 the concept arose that FGFR1 is the “metabolic” FGFR while FGFR4 is the 
“proliferative” FGFR (Adams et al., 2013; Wu et al., 2009; Wu et al., 2011). This 
concept seems to be valid in many cases, and has proved to be useful in the design 
of FGF variants with reduced mitogenic properties.  
FGF1 mutants 
Already in the nineties it has been shown that the N-terminus of FGF1 is involved 
in the proliferative properties of FGF1 (Imamura et al., 1990). In addition, it has been 
shown that the N-terminus (amino acids 1-15) is important for the anorexic effects of 
FGF1 in the brain (Sasaki et al., 1995). More recently, the FGF1 variant FGF1dNT 
was described. This mutant lacks the first 24 amino acids from the N-terminus, and 
shows slightly reduced binding affinity for FGFR1 and 2, and virtually no affinity for 
FGFR3 and FGFR4. With the deletion of the N-terminus also the proliferative 
properties of FGF1dNT on the NIH 3T3 fibroblast cell line disappeared, while the in 
vivo insulin-sensitizing effects were conserved (Suh et al., 2014). Another FGF1 
mutant, R50E no longer binds to integrin ανβ3, but can still bind to FGFR1 and 
heparin (Mori et al., 2008). Although it can still stimulate transient ERK 
phosphorylation, this activation cannot be sustained and consequently shows 
reduced effects on cell proliferation and cell migration (Yamaji et al., 2010). 
Moreover, this mutant was able to suppress the angiogenic and tumorigenic effects 
of FGF1 and FGF2 in several different in vivo and in vitro models (Mori et al., 2013).  
Because FGF1 can stimulate angiogenesis it is currently under investigation 
whether for the treatment of ischemia and wound healing. However, its poor bio-
stability currently limits its application. Attempts to improve the stability of the protein 
showed that by only changing a few amino acids within the protein (Lys12 Val and 
Pro134Val) it is possible to greatly improve the half-life and stability of FGF1 (Xia et 
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al., 2012). In addition, PEG-ylation of FGF1 leads to increased half-life in vivo and 
improved pharmacological activity (Huang et al., 2011). Whether the FGF1 R50E 
mutant, the thermostabilized mutant and the PEG-ylated mutant hold promise for 
FGF1-based treatment of metabolic disease remains to be determined.  
 
 
Scope and outline of the thesis  
    Nuclear Receptors (NRs) comprise a family of 48 ligand-modulated transcription 
factors (TFs) that mediate responses to a wide range of lipophilic signaling molecules 
including lipids, steroids, retinoids, hormones and xenobiotics. As sensors for these 
signals they provide an important link between transcriptional regulation and 
physiology. Their general ability to bind ligands makes this family an ideal therapeutic 
target. Indeed, 13% of FDA approved drugs targets the NR-family and includes drugs 
for the treatment of insulin resistance (TZDs), hyperlipidemia (fibrates), inflammation 
(dexamethasone) and cancer (tamoxifen) (Overington et al., 2006). Thus, NRs have 
become a primary target for drug development aimed at metabolic disease.  
    The main focus of our research is to study the regulatory mechanisms of these 
nuclear receptors and to explore their therapeutic value in the treatment of metabolic 
diseases. To do this, our lab has developed a powerful functional high through-put 
screen that has previously led to the identification of Fibroblast Growth Factor 1 
(FGF1) as a target of nuclear receptor PPARγ in visceral adipose tissue (Jonker et 
al., Nature 2012) and subsequently its establishment as a critical regulator of 
metabolic homeostasis and insulin sensitivity (Suh et al., Nature 2014).  
    In this thesis, we have applied this functional screen to investigate the regulation of 
insulin by members of the NR family. The first experimental part of this thesis 
describes the identification of insulin as a target of orphan nuclear receptor TR4 
(chapter 2) and the subsequent characterization of its role in the development of 
type 2 diabetes using β-cell specific TR4 knockout mice (chapters 3). The second 
part of this thesis focused on the use of FGF1 in the treatment of non-alcoholic fatty 
liver disease (chapters 4 ) and its underlying mechanism (chapter 5). Finally, the 
implications of the present results are discussed in the light of the existing literature, 
as well as the implications for future research (chapter 6). 
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